Publications by authors named "Jean Hugues Salmon"

Article Synopsis
  • The French Society of Rheumatology updated its recommendations for managing rheumatoid arthritis (RA) based on the latest EULAR guidelines, involving a wide range of experts and patient representatives.
  • The guidelines stress the importance of shared decision-making and comprehensive management for individuals with RA or those at risk, focusing on both drug and non-drug therapies.
  • Additional emphasis is on the diagnosis and treatment of RA-related interstitial lung disease (RA-ILD), highlighting the need for collaboration between rheumatologists and pulmonologists for effective management.
View Article and Find Full Text PDF

Background: Uncontrolled gout can cause articular impairment but is also associated with a global and cardiovascular excess mortality, especially in dialysis population. Data documented within existing research is not conclusive regarding gout flares evolution during hemodialysis and their control by urate lowering therapy (ULT). Without clear guidelines concerning hemodialysis patients management with chronic gout, this study proposes to investigate whether gout flare incidence reduction could be observed on this population treated by urate lowering therapy versus patients without treatment.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to evaluate adherence to methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients using a new urinary dosage method (METU) and compare it to traditional adherence measurements.* -
  • The research involved 84 RA patients at Reims University Hospital, revealing that 91.7% were considered adherent according to METU, while indirect methods (Medication Possession Ratio and Compliance Questionnaire of Rheumatology) indicated lower adherence rates.* -
  • The results suggest that indirect adherence assessments may not accurately reflect real-life adherence, highlighting the importance of using METU for better understanding treatment responses in RA patients.*
View Article and Find Full Text PDF

Background: The least significant change (LSC) threshold of 0.03 g/cm² is used to interpret bone mineral density (BMD) scans in the general population. Our working hypothesis was that the current LSC threshold would not be applicable in obese populations.

View Article and Find Full Text PDF

We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharmacovigilance database, we estimated the RR of PMR and GCA cases in individuals aged over 50 who developed their initial symptoms within one month of receiving the BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, and Ad26.COV2.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the retention rates, safety, and predictive factors for the use of subcutaneous TNF inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) based on real-life data from 552 patients.
  • Results indicated that golimumab (GOL) had a significantly higher retention rate compared to adalimumab (ADA), etanercept (ETN), and certolizumab pegol (CZP), especially when prescribed as the first treatment option.
  • Predictive factors for treatment cessation included female sex, peripheral disease, and the line of treatment, with primary inefficiency being the most common reason for stopping treatment.
View Article and Find Full Text PDF

Background And Objectives: Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis (RA). While therapeutic adherence is essential to successful management, no objective MTX assay is currently available. Using population pharmacokinetic modelling (PopPK), our objective was to describe the urinary MTX (MTXu) kinetics in treated patients and to evaluate its abilities to assess the MTX-adherence.

View Article and Find Full Text PDF

Introduction: RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time to discontinuation of initial RA treatment along with patient baseline characteristics. This study's primary objective was to assess the time to discontinuation of initial baricitinib, any other targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD), or any biologic disease-modifying anti-rheumatic drug (bDMARD) treatment for all causes (excluding sustained clinical response) over 24 months in a European population.

Methods: Patients initiated treatment with baricitinib (cohort A) or any bDMARD or tsDMARD (cohort B) for the first time.

View Article and Find Full Text PDF

Background: Patients with rheumatoid arthritis (RA) and other chronic inflammatory rheumatic disorders have increased risk of cardiovascular disease (CVD) and venous thromboembolism (VTE) compared with the general population. Moreover, recent data have raised concerns around a possible increased risk of major CV events (MACE) and VTE in patients treated with JAK inhibitors (JAKi). In October 2022, the PRAC has recommended measures to minimize the risk of serious side effects, including CV conditions and VTE, associated with all approved in chronic inflammatory diseases.

View Article and Find Full Text PDF

Many studies have shown the effectiveness of platelet-rich plasma (PRP) in the treatment of knee osteoarthritis. We aimed to determine the factors associated with good or poor response to PRP injections in knee osteoarthritis. This was a prospective observational study.

View Article and Find Full Text PDF

Survival improvement in cystic fibrosis (CF) is associated with more frequent long-term complications, including CF related bone disease (CFBD). Impact of CFBD on global health outcome remains poorly described. We aimed to assess the relationship between low bone mineral density (BMD) and spinal pain, disability, and quality of life in CF adult patients.

View Article and Find Full Text PDF
Article Synopsis
  • Previous studies showed that biosimilars (bsDMARDs) and original treatments (boDMARDs) are similarly effective and safe, but less is known about their performance in naïve patients starting treatment for the first time.
  • This study aimed to compare the treatment retention rates of bsDMARDs and boDMARDs across different diseases (like RA, SpA, and PsA) and specific molecules (etanercept and adalimumab), while also identifying predictive factors influencing treatment retention.
  • Results indicated that bsDMARDs had a longer retention rate than boDMARDs (39 months vs. 23 months), particularly for etanercept in rheumatoid arthritis patients, and treatments containing citrate showed even better retention.*
View Article and Find Full Text PDF

Introduction: RA-BE-REAL has the overall aim of defining a profile of patients with rheumatoid arthritis (RA) starting baricitinib or any other targeted synthetic (ts) or any biologic (b) disease-modifying antirheumatic drug (DMARD) for the first time, and the primary objective of estimating time until discontinuation from any cause (excluding sustained response) of the initial treatment.

Methods: RA-BE-REAL is an ongoing, prospective, observational, 36-month study in patients with RA initiating treatment with baricitinib (cohort A) or any other tsDMARD or any bDMARD (cohort B) for the first time. The primary objective is to assess the time until treatment discontinuation from any cause (excluding sustained response) at 24 months, (i.

View Article and Find Full Text PDF

Background: Use of a combination of targeted therapies (COMBIO) in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs) has increased, but reported data remain scarce. We aimed to assess effectiveness and safety of COMBIO in patients with IMIDs.

Methods: We conducted a French ambispective multicenter cohort study from September 2020 to May 2021, including adults' patients with 1 or 2 IMIDs and treated at least 3-month with COMBIO.

View Article and Find Full Text PDF
Article Synopsis
  • A study looked at people who survived severe COVID-19 to see how it affected their breathing, muscles, and mental health three months later.
  • They found that many patients had ongoing breathing problems, muscle weakness, and even signs of anxiety or PTSD.
  • The research showed that a specific group of patients had the worst symptoms, but their issues weren't linked to how sick they were during COVID-19.
View Article and Find Full Text PDF

Introduction: We aimed to evaluate the efficacy and tolerance of A1 pulley release using the needle technique, under ultrasound guidance, in patients with symptomatic trigger finger.

Methods: All patients with symptomatic trigger finger underwent A1 pulley release using an intramuscular 21 gauge (G) needle. Quinnell grade (I-IV), Quick Disabilities of Arm, Shoulder & Hand (QuickDASH) score (0-100) and pain score on a visual analog scale (VAS: 0-10mm) were recorded at inclusion.

View Article and Find Full Text PDF

Background: Obesity is a risk factor for dyspnea. However, investigations of daily living obesity-related dyspnea are limited and its mechanisms remain unclear. We conducted a cross-sectional study to analyze the relationships between dyspnea in daily living, lung function, and body composition in patients with obesity.

View Article and Find Full Text PDF
Article Synopsis
  • - The study examined the prevalence of spinal and joint pain in adults with cystic fibrosis (CF) and how it affects their disability, anxiety, depression, and quality of life.
  • - Out of 47 patients analyzed, 47% reported experiencing rheumatologic pain, which was associated with factors like shorter height and more severe CF-related symptoms.
  • - The findings suggest that rheumatologic pain is common among CF patients and significantly impacts their daily functioning and mental health, highlighting the need for regular pain assessments in their treatment plans.
View Article and Find Full Text PDF

: Biologic treatments are a milestone in the management of rheumatoid arthritis (RA) patients with an inadequate response to conventional synthetic treatments. With the increase in the number of biologic treatments, predictor factors of discontinuation are needed to choose the right treatment for the right patient.: In this article, the factors affecting persistence with biologic treatments will be covered: factors associated with the demographic characteristics and comordidities of the patients, those with the characteristics of the disease, the biomarkers, and the adherence.

View Article and Find Full Text PDF